CD8A and neoplasm: Additionally, we reported an increase in tumor antigen-specific CD8+ T cells from the αTIGIT + bintrafusp alfa Responders cohort in comparison to untreated control animals on day 17 and day 24 post-tumor inoculation (Figure 5 f and g, left panels).